Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
BMC Infect Dis ; 7: 40, 2007 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-17493279

RESUMO

BACKGROUND: Fusarium spp. is being isolated with increasing frequency as a pathogen in oncohematologic patients. Caspofungin and amphotericin B have been reported to have synergistic activity against Fusarium spp. CASE PRESENTATION: We herein report a case of disseminated fusariosis diagnosed by chest CT scan and positive blood cultures to Fusarium spp. Because the patient's clinical condition deteriorated, CRP levels increased, and blood cultures continued to yield Fusarium spp. despite liposomal amphotericin B monotherapy up to 5 mg/kg daily, treatment with caspofungin was added. Within 2 weeks of onset of combined antifungal therapy, the chest CT scan demonstrated a progressive resolution of the pulmonary lesions. Upon discontinuation of intravenous antifungals, the patient received suppressive therapy with oral voriconazole. Three months later, a chest CT scan showed no abnormalities. Twenty-five months after discontinuation of all antifungal therapy, the patient remains in complete remission of her neoplastic disease with no signs of clinical activity of the Fusarium infection. CONCLUSION: This is the first description of successful treatment of disseminated fusariosis in a pediatric patient with acute lymphoblastic leukemia with caspofungin and amphotericin B followed by oral suppressive therapy with voriconazole.


Assuntos
Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Fusarium/efeitos dos fármacos , Micoses/tratamento farmacológico , Peptídeos Cíclicos/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Anfotericina B/administração & dosagem , Antifúngicos/administração & dosagem , Caspofungina , Criança , Quimioterapia Combinada , Equinocandinas , Feminino , Fusarium/classificação , Humanos , Lipopeptídeos , Micoses/complicações , Micoses/microbiologia , Peptídeos Cíclicos/administração & dosagem , Pirimidinas/administração & dosagem , Pirimidinas/uso terapêutico , Resultado do Tratamento , Triazóis/administração & dosagem , Triazóis/uso terapêutico , Voriconazol
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA